Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving tipifarnib together with fulvestrant works as
second-line therapy in treating postmenopausal women with hormone receptor-positive
inoperable locally advanced or metastatic breast cancer that has progressed after previous
first-line endocrine therapy. Tipifarnib may stop the growth of tumor cells by blocking the
enzymes necessary for their growth. Estrogen can stimulate the growth of breast cancer cells.
Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen.
Combining tipifarnib with fulvestrant may kill tumor cells that did not respond to first-line
therapy.